Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32669540 | 0.82 | MMP2 (0.34) | MRGPRX4ALDH1A1 | |
| SCHEMBL32670074 | 0.82 | KMT2A (0.39) | ESR1RAB9AKMT2AALDH1A1LMNA | |
| SCHEMBL32669776 | 0.81 | GRM2 (0.33) | — | |
| SCHEMBL32669580 | 0.81 | COMT (0.35) | ESR1 | |
| SCHEMBL32669930 | 0.81 | RAB9A (0.38) | ESR1RAB9AKMT2AKDM4EALDH1A1 | |
| SCHEMBL32669882 | 0.81 | HRH1 (0.34) | RAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL32669823 | 0.80 | KMT2A (0.40) | MRGPRX4RAB9AKMT2AKDM4EALDH1A1 | |
| SCHEMBL32669869 | 0.78 | RAB9A (0.42) | ESR1RAB9AKMT2A | |
| SCHEMBL32669974 | 0.77 | COMT (0.36) | ALDH1A1 | |
| SCHEMBL32669511 | 0.76 | COMT (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | ESR1 1076/4885MRGPRX4 4062/4885RAB9A 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.